Previous 10 | Next 10 |
COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company ...
The company recently merged with BioClonetics and plans to develop treatments for HIV and COVID-19. However, there are no revenues and its Bulgarian partner denies that Enzolytics has a stake in it. Enzolytics has a valuation of $982.1 million but I don’t think the business...
Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites. COLLEGE STATION,TX / ACCESSWIRE / March 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has filed for patent protection on t...
Reddit Penny Stocks Continue Surging But Are They Worth The Risk? The stock market continues selling off today and many penny stocks weren’t immune to this drop either. Even some of the sectors that tend to perform well in environments like this were seen pulling back during Frid...
Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has identified eleven conserved, expectedly immutable sites...
COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the execution of Articles of Association to form International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The ...
COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was test...
Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserve...
Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS. The company's treatment appears to be different from other treatments. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effec...
Third Tranche of $1.2 Million Financing Completed COLLEGE STATION, TX / ACCESSWIRE / January 19, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent applicatio...
News, Short Squeeze, Breakout and More Instantly...
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( enzolytics.com ) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and i...
BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to fa...
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated pepsin frag...